SEC Comment Letter 0000000000-26-001655 to Nuvectis Pharma, Inc. (NVCT)

Nuvectis Pharma, Inc.
Date: Feb. 18, 2026 · CIK: 0001875558 · Accession: 0000000000-26-001655

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-293459

Date

February 18, 2026

Author

Division of

Form

UPLOAD

Company

Nuvectis Pharma, Inc.

Letter

Re: Nuvectis Pharma, Inc. Registration Statement on Form S-3 Filed February 13, 2026 File No. 333-293459 Dear Ron Bentsur:

February 18, 2026

Ron Bentsur Chief Executive Officer Nuvectis Pharma, Inc. 1 Bridge Plaza Suite 275 Fort Lee, NJ 07024

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Tyler Howes at 202-551-3370 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Matthew Mamak, Esq.

Show Raw Text

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
                                                           February 18, 2026

Ron Bentsur
Chief Executive Officer
Nuvectis Pharma, Inc.
1 Bridge Plaza
Suite 275
Fort Lee, NJ 07024

       Re: Nuvectis Pharma, Inc.
           Registration Statement on Form S-3
           Filed February 13, 2026
           File No. 333-293459
Dear Ron Bentsur:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Tyler Howes at 202-551-3370 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:    Matthew Mamak, Esq.
</TEXT>
</DOCUMENT>

SecProbe.io